Mirum Pharmaceuticals, Inc.
MIRM
Kedudukan dalam Saham
#3346
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Harga Saham
$80.17
Disegerakkan terakhir: 2026-10-16
Modal Pasaran
$5.21B
Perubahan (1 hari)
-2.69%
Perubahan (1 tahun)
9.03%
Negara
US
Perdagangan Mirum Pharmaceuticals, Inc. (MIRM)
Kategori
Healthcare
EPS untuk Mirum Pharmaceuticals, Inc. (MIRM)
EPS setakat June 2026 TTM: $-14.56
Menurut laporan kewangan terkini dan harga saham Mirum Pharmaceuticals, Inc., EPS semasa syarikat (TTM) adalah $-14.56. Pada akhir tahun 2023, syarikat mempunyai EPS sebanyak $-4.00 penurunan berbanding EPS tahun 2022 iaitu $-4.01.
Sejarah EPS untuk Mirum Pharmaceuticals, Inc. dari 2018 hingga 2026
EPS pada akhir setiap tahun
| Tahun | EPS | Ubah |
|---|---|---|
| 2026 (TTM) | $-14.56 | 687.03% |
| 2024 | $-1.85 | -53.75% |
| 2023 | $-4.00 | -0.25% |
| 2022 | $-4.01 | 44.77% |
| 2021 | $-2.77 | -32.27% |
| 2020 | $-4.09 | 78.60% |
| 2019 | $-2.29 | 205.33% |
| 2018 | $-0.75 | 0.00% |
EPS untuk syarikat atau pesaing yang serupa
| Syarikat | EPS | Perbezaan EPS | Negara |
|---|---|---|---|
| $17.32 | -218.96% |
US
|
|
| $-7.98 | -45.19% |
US
|
|
| $-5.29 | -63.67% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -290.52% |
NL
|
